Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RGNX?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, particularly for investors who purchased securities between February 9, 2022, and January 27, 2026, highlighting a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing contact numbers 877-247-4292 and 212-983-9330, aiming to assist investors in understanding their legal rights and taking necessary actions.
- Class Action Reminder: Faruq & Faruqi reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.900
Low
19.00
Averages
29.71
High
45.00
Current: 7.900
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, particularly for investors who purchased securities between February 9, 2022, and January 27, 2026, highlighting a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing contact numbers 877-247-4292 and 212-983-9330, aiming to assist investors in understanding their legal rights and taking necessary actions.
- Class Action Reminder: Faruq & Faruqi reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Notice to REGENXBIO Shareholders Regarding Class Action
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased REGENXBIO (NASDAQ:RGNX) shares between February 9, 2022, and January 27, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that REGENXBIO misled investors about the development of its RGX-111 gene therapy by providing false and misleading information while concealing significant adverse facts regarding the therapy's efficacy and safety.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock price to plummet 17.8% in one day, from $13.41 to $11.01 per share.
- Registration Deadline: Shareholders must register for this class action by April 14, 2026, and will receive status updates throughout the case lifecycle, with no cost or obligation to participate.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against REGENXBIO on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, with a deadline for lead plaintiff motions set for April 14, 2026, indicating the urgency of legal action.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 after an intraventricular CNS tumor was found in a trial participant, leading to a nearly 18% drop in stock price, reflecting serious market concerns about product safety.
- Allegations of False Statements: The lawsuit alleges that defendants disseminated false and misleading statements during the class period, concealing material adverse facts regarding the efficacy and safety of the RGX-111 trial, which could result in significant financial losses for investors, highlighting potential governance issues within the company.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights for pursuing claims to recover losses, demonstrating the firm's commitment to supporting and compensating affected investors.
See More
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Drug Safety Issues: The complaint claims that while REGENXBIO touted RGX-111's FDA Fast Track designation in 2018 and reported positive clinical trial results, the company was aware of serious safety concerns, including the potential for central nervous system tumors.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor, causing REGENXBIO's stock to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, while those who choose not to participate can remain absent class members eligible for recovery.
See More
REGENXBIO Faces Class Action Lawsuit Over Allegations of Misleading Information
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against REGENXBIO in the U.S. District Court for the Southern District of Maryland on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that REGENXBIO misled investors regarding the development of its gene therapy RGX-111 by providing overly optimistic trial success forecasts while concealing critical adverse facts about the trial's safety and efficacy, potentially leading to investor losses.
- Stock Price Plunge: Following the FDA's clinical hold on RGX-111, REGENXBIO's stock price plummeted from $13.41 per share on January 27, 2026, to $11.01 on January 28, representing a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Affected investors have until April 14, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and potential remedies.
See More
REGENXBIO Faces Securities Litigation Investigation
- Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
- Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
- Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.
See More
Faruqi & Faruqi Investigates Potential Claims Against REGENXBIO
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against REGENXBIO, particularly for investors who purchased securities between February 9, 2022, and January 27, 2026, highlighting a commitment to protecting investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing contact numbers 877-247-4292 and 212-983-9330, aiming to assist investors in understanding their legal rights and taking necessary actions.
- Class Action Reminder: Faruq & Faruqi reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against REGENXBIO, emphasizing the importance of timely action.
- Potential Market Impact: This investigation may negatively affect REGENXBIO's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Notice to REGENXBIO Shareholders Regarding Class Action
- Shareholder Action Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased REGENXBIO (NASDAQ:RGNX) shares between February 9, 2022, and January 27, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations Overview: The complaint alleges that REGENXBIO misled investors about the development of its RGX-111 gene therapy by providing false and misleading information while concealing significant adverse facts regarding the therapy's efficacy and safety.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock price to plummet 17.8% in one day, from $13.41 to $11.01 per share.
- Registration Deadline: Shareholders must register for this class action by April 14, 2026, and will receive status updates throughout the case lifecycle, with no cost or obligation to participate.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against REGENXBIO on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, with a deadline for lead plaintiff motions set for April 14, 2026, indicating the urgency of legal action.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 after an intraventricular CNS tumor was found in a trial participant, leading to a nearly 18% drop in stock price, reflecting serious market concerns about product safety.
- Allegations of False Statements: The lawsuit alleges that defendants disseminated false and misleading statements during the class period, concealing material adverse facts regarding the efficacy and safety of the RGX-111 trial, which could result in significant financial losses for investors, highlighting potential governance issues within the company.
- Legal Support and Compensation: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss their legal rights for pursuing claims to recover losses, demonstrating the firm's commitment to supporting and compensating affected investors.
See More
REGENXBIO Faces Class Action Lawsuit
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
- Drug Safety Issues: The complaint claims that while REGENXBIO touted RGX-111's FDA Fast Track designation in 2018 and reported positive clinical trial results, the company was aware of serious safety concerns, including the potential for central nervous system tumors.
- FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor, causing REGENXBIO's stock to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, while those who choose not to participate can remain absent class members eligible for recovery.
See More
REGENXBIO Faces Class Action Lawsuit Over Allegations of Misleading Information
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against REGENXBIO in the U.S. District Court for the Southern District of Maryland on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that REGENXBIO misled investors regarding the development of its gene therapy RGX-111 by providing overly optimistic trial success forecasts while concealing critical adverse facts about the trial's safety and efficacy, potentially leading to investor losses.
- Stock Price Plunge: Following the FDA's clinical hold on RGX-111, REGENXBIO's stock price plummeted from $13.41 per share on January 27, 2026, to $11.01 on January 28, representing a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
- Investor Rights Protection: Affected investors have until April 14, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and potential remedies.
See More
REGENXBIO Faces Securities Litigation Investigation
- Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
- Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
- Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.
See More
